# A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients

> **NCT03145961** · PHASE2 · UNKNOWN · sponsor: **Institute of Cancer Research, United Kingdom** · enrollment: 208 (actual)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03145961
- **Lead sponsor:** Institute of Cancer Research, United Kingdom
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-12-21
- **Primary completion:** 2021-09-30
- **Final completion:** 2024-03-31
- **Target enrollment:** 208 (ACTUAL)
- **Last updated:** 2022-02-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03145961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03145961, "A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03145961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*